Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023
Publication date
2024-01-04
Authors
Van Werkhoven, Cornelis H.
Valk, Anne Wil
Smagge, Bente
de Melker, Hester E.
Knol, Mirjam J.
Hahné, Susan JM
van den Hof, Susan
de Gier, Brechje
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults≥60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6–74.3), VE against ICU admission was 73.3% (95% CI: 42.2–87.6).
Keywords
Epidemiology, Public Health, Environmental and Occupational Health, Virology
Citation
van Werkhoven, C H, Valk, A W, Smagge, B, de Melker, H E, Knol, M J, Hahné, S JM, van den Hof, S & de Gier, B 2024, 'Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023', Eurosurveillance, vol. 29, no. 1, 2300703. https://doi.org/10.2807/1560-7917.ES.2024.29.1.2300703